Toggle Nav
My Cart
English
Español
Menu
Account
  • Log in / Register
    • Language
    English
    Español

    Merck: Investing in Science-Based Business (Abridged)

    Raman, Ananth ; Maurer, Inga

    • Reference: HBS-611027-E

    • Year: 2004

    • Number of pages: 5

    • Geographic Setting: New Jersey;United States

    • Publication Date: Sep 24, 2010

    • Source: HBSP (USA)

    • Type of Document: Case

    • Industry Setting: Pharmaceuticals

    Grouped product items
    Format Language Reference Use Qty Price
    pdf English HBS-611027-E
    As low as €8.20

    You already have a subscription
    To order please contact the person in charge of academic purchases in your university.
    You'll be able to order once your profile has been validated.

    Description

    Ray Gilmartin faces a dilemma. His company's credibility has been damaged by the recent withdrawal of Vioxx, a multi-billion dollar drug. Moreover, the withdrawal of Vioxx would imply that Merck would fail to meet analysts' earnings expectations for 2005 unless Gilmartin cuts the R&D budget. Cutting the budget might hurt morale and productivity in Merck labs.

    Keywords

    Investments Operations and processes R&D